Work

Case Report: Abscopal effect in a patient with refractory metastatic hepatocellular carcinoma treated with stereotactic body radiotherapy and PD-1 inhibitor

Year: 2025

Type: article

Abstract: There is currently no established standard treatment for patients with metastatic hepatocellular carcinoma after resistance to tyrosine kinase inhibitors. Given that radiotherapy can reprogram the tumor microenvironment and convert "cold" tumors into "hot" tumors, combining radiotherapy with immunotherapy shows significant potential. In this case, we present a male patient with HBV-related metastatic hepatocellular carcinoma (HCC) accompanied by portal vein tumor thrombosis. The patient achieved abscopal effect with a progression-free survival of 10 months and an overall survival of 21 months with the combination of anti-PD-1 therapy and stereotactic body radiotherapy (SBRT) as third-line treatment. This combination therapy demonstrates relative efficacy and favorability in treating HBV-related advanced HCC.

Source: Frontiers in Immunology

DOI: 10.3389/fimmu.2025.1536689

Authors: Pei Shu, Fang Wang, Xin Wang

Institutions: Sichuan University, West China Hospital of Sichuan University

Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,801